Recommendation of the President – Olumiant (baricytynib)
On 27 May 2022 the President of the Agency for Health Technology Assessment and Tariff System issued the following recommendation:
Recommendation No. 48/2022 of 27 May 2022 of the President of the Agency for Health Technology Assessment and Tariff System on the evaluation of Olumiant (baricytynib) under the drug programme: “Treatment of patients with severe and moderate forms of atopic dermatitis (ICD-10: L20)”